ARMP
insider transactionsArmata Pharmaceuticals, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
51.3K sh
Own New
-
Other·F
Chief Business Officer
$10.9K
1.0K sh · $10.54
Own -10%
-
Other·F
Deborah Birx KEY
Chief Executive Officer
$51.8K
4.9K sh · $10.54
Own -2%
-
Grant·A
Director
$0
25.6K sh
Own New
-
Grant·A
Chief Business Officer
$0
183.1K sh
Own New
-
Grant·A
SVP, Finance, and PFO
$0
109.9K sh
Own New
-
Grant·A
Director
$0
25.6K sh
Own New
-
Grant·A
Director
$0
25.6K sh
Own New
-
Grant·A
Director
$0
25.6K sh
Own New
-
Grant·A
Deborah Birx KEY
Chief Executive Officer
$0
421.2K sh
Own New
-
Grant·A
Director
$0
25.6K sh
Own New
-
Grant·A
Director
$0
25.6K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Apr 24, 2026 | Daniel B. Gilmer | Grant A | 51.3K | $0 |
| Mar 14, 2026 | Pierre Kyme | Other F | 1.0K | $10.9K |
| Mar 14, 2026 | Deborah Birx KEY | Other F | 4.9K | $51.8K |
| Mar 9, 2026 | Robin Kramer | Grant A | 25.6K | $0 |
| Mar 9, 2026 | Pierre Kyme | Grant A | 183.1K | $0 |
| Mar 9, 2026 | David Duane House | Grant A | 109.9K | $0 |
| Mar 9, 2026 | Joseph M Patti | Grant A | 25.6K | $0 |
| Mar 9, 2026 | Todd C. Peterson | Grant A | 25.6K | $0 |
| Mar 9, 2026 | Kostas D Odysseas | Grant A | 25.6K | $0 |
| Mar 9, 2026 | Deborah Birx KEY | Grant A | 421.2K | $0 |
| Mar 9, 2026 | Sarah J. Schlesinger | Grant A | 25.6K | $0 |
| Mar 9, 2026 | Jules Haimovitz | Grant A | 25.6K | $0 |
About ARMP insider trading
This page tracks insider transactions for Armata Pharmaceuticals, Inc. (ARMP) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.